Charles River Laboratories Remaining performance obligations
Remaining performance obligations at Charles River Laboratories came to $675.3M at 26 Sep 2026, up 4.0% from a year earlier.
As Charles River Laboratories reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 4 Nov 2026.
By quarter
| Period ending | Remaining performance obligations | Change on a year | Filed |
|---|---|---|---|
| 26 Sep 2026 | $675.3M | up 4.0% | 4 Nov 2026 |
| 27 Jun 2026 | $699.9M | down 3.8% | 5 Aug 2026 |
| 28 Mar 2026 | $702.2M | down 10.2% | 7 May 2026 |
| 27 Dec 2025 | $667.1M | down 15.4% | 18 Feb 2026 |
| 27 Sep 2025 | $649.3M | down 19.2% | 5 Nov 2025 |
| 28 Jun 2025 | $727.3M | down 15.1% | 6 Aug 2025 |
| 29 Mar 2025 | $781.9M | down 15.1% | 7 May 2025 |
| 28 Dec 2024 | $788.5M | down 20.0% | 19 Feb 2025 |
| 28 Sep 2024 | $803.5M | down 16.1% | 6 Nov 2024 |
| 29 Jun 2024 | $856.6M | down 16.8% | 7 Aug 2024 |
| 30 Mar 2024 | $920.5M | down 17.3% | 9 May 2024 |
| 30 Dec 2023 | $986.0M | down 18.0% | 14 Feb 2024 |
| 30 Sep 2023 | $957.7M | down 16.6% | 8 Nov 2023 |
| 1 Jul 2023 | $1.0B | up 4.3% | 9 Aug 2023 |
| 1 Apr 2023 | $1.1B | up 29.6% | 11 May 2023 |
| 31 Dec 2022 | $1.2B | up 67.9% | 22 Feb 2023 |
| 24 Sep 2022 | $1.1B | up 88.4% | 2 Nov 2022 |
| 25 Jun 2022 | $987.1M | up 90.9% | 3 Aug 2022 |
| 26 Mar 2022 | $859.0M | up 145.3% | 4 May 2022 |
| 25 Dec 2021 | $716.5M | up 97.2% | 16 Feb 2022 |
| 25 Sep 2021 | $609.5M | up 61.2% | 3 Nov 2021 |
| 26 Jun 2021 | $517.0M | up 29.1% | 4 Aug 2021 |
| 27 Mar 2021 | $350.2M | up 12.3% | 4 May 2021 |
| 26 Dec 2020 | $363.2M | — | 17 Feb 2021 |
| 26 Sep 2020 | $378.1M | — | 29 Oct 2020 |
| 27 Jun 2020 | $400.6M | — | 5 Aug 2020 |
| 28 Mar 2020 | $312.0M | — | 7 May 2020 |
| 31 Mar 2018 | $73.0M | — | 10 May 2018 |
Definition
Revenue under signed contracts that the company has not yet recognised: deferred revenue plus amounts it will invoice and recognise later (ASC 606). Stated at each balance-sheet date. Companies may leave out contracts of a year or less. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Charles River Laboratories: Organic revenue (change on a year) · Revenue · Cost of services provided (excluding amortization of intangible assets) revenue · Cost of products sold (excluding amortization of intangible assets) revenue · DSA revenue · RMS revenue · Manufacturing revenue · United States revenue · Europe revenue · Canada revenue · Asia Pacific revenue · financial statements
Every KPI and segment of CRL, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
